CD74 is a potential biomarker predicting the response to immune checkpoint blockade.

ABSTRACT:

Background

Immune checkpoint blockade (ICB) has been improving the patient outcome in multiple cancer types. However, not all patients respond to ICB. Biomarkers are needed for selecting appropriate patients to receive ICB. CD74 is an important chaperone that regulates antigen presentation for immune response. However, the relationship between CD74 expression and ICB response remains elusive.

Methods

The unified normalized pan-cancer dataset was downloaded from the UCSC database. Wilcoxon Rank Sum Rank Tests were used to analyze the expression differences between normal and tumor samples in each tumor type. Then, the prognostic value of CD74 was determined using univariable Cox proportional hazards regression analysis. The STRING database was utilized to construct the protei

SUBMITTER: Shi WQ 

PROVIDER: S-EPMC11476377 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature